Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 6/20 | 0.71 |
| ▸ | HPGD | P15428 | 5/20 | 0.71 |
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | GFER | P55789 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5465217 | 0.89 | ALDH1A1 (0.81) | FLT3HPGDLMNAALDH1A1MEN1 | |
| SCHEMBL1007246 | 0.89 | FLT3 (0.75) | FLT3HPGDLMNAALDH1A1MEN1 | |
| SCHEMBL4135422 | 0.89 | HPGD (0.83) | FLT3HPGDLMNAALDH1A1MEN1 | |
| SCHEMBL5455950 | 0.86 | HPGD (0.83) | FLT3HPGDLMNAALDH1A1MEN1 | |
| SCHEMBL31562921 | 0.86 | KDM4E (0.75) | FLT3HPGDLMNAALDH1A1MEN1 | |
| SCHEMBL3452692 | 0.84 | MEN1 (0.59) | FLT3HPGDLMNAALDH1A1MEN1 | |
| SCHEMBL5454380 | 0.84 | FLT3 (0.72) | FLT3HPGDLMNAALDH1A1MEN1 | |
| SCHEMBL5457782 | 0.84 | ALDH1A1 (0.95) | FLT3HPGDLMNAALDH1A1MEN1 | |
| SCHEMBL5453467 | 0.83 | FLT3 (1.00) | FLT3HPGDLMNAALDH1A1MEN1 | |
| SCHEMBL3453042 | 0.83 | FLT3 (0.75) | FLT3HPGDLMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| EP-2041124-B1 | PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS | MSD OSS BV (NL) | 2013-06-26 | — | — | EP | disclosed |
| US-7820707-B2 | Heterocyclic derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| US-7820707-B2 | Heterocyclic derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| US-7820707-B2 | Heterocyclic derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| EP-2041124-A1 | PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS | N.V. Organon (NL) | 2009-04-01 | — | — | EP | disclosed |
| US-20080255086-A1 | Heterocyclic Derivatives | N.V. ORGANON (NL) | 2008-10-16 | — | — | US | disclosed |
| US-20080255086-A1 | Heterocyclic Derivatives | N.V. ORGANON (NL) | 2008-10-16 | — | — | US | disclosed |
| US-20080255086-A1 | Heterocyclic Derivatives | N.V. ORGANON (NL) | 2008-10-16 | — | — | US | disclosed |
| WO-2008003452-A1 | PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS | N.V. ORGANON (NL) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008003452-A1 | PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS | N.V. ORGANON (NL) | 2008-01-10 | — | — | WO | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | FLT3 3509/4885HPGD 2361/4885LMNA 3232/4885 |
| US-20080255086-A1 | Heterocyclic Derivatives | GRIN2C, GRIN3A, GRIN1 | FLT3 658/4885HPGD 329/4885LMNA 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.